AGTC to Participate in Upcoming Investor and Scientific Conferences

GAINESVILLE, Fla., and CAMBRIDGE, Mass., March 07, 2016 -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that company management will participate in four upcoming investor and scientific conferences.

• Boston Biotech Conferences: BD Boston – Boston, Mass. (March 9)
  Stephen Potter, Chief Business Officer, will be speaking on a panel entitled “Managing Shareholder Expectations while Focusing on Growth” on Wednesday, March 9th at 3:45pm EST. Stephen and other leaders of the financial and biotech communities will share their experience in supporting a growing company via shareholder-executive relationships.
  
  

• 28^th Annual ROTH Conference – Dana Point, Calif. (March 13-16)
  On Tuesday, March 15th at 10:00am PDT (1:00pm EDT), Sue Washer, President and CEO, will deliver a corporate overview discussing the company's lead programs in ophthalmology, including X-linked retinoschisis (XLRS), achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). To access a live webcast of this presentation, please visit http://ir.agtc.com/. A replay will be available for one month following the conference.
  
  

• 8^th Ocular Diseases Drug Discovery Conference– San Diego, Calif. (March 21-22)
  Mark Shearman, Ph.D., Chief Scientific Officer, will lead a session titled "Clinical Development of rAAV Gene Therapy for Inherited Retinal Disorders," on Monday, March 21st at 1:55pm PDT (4:55pm EDT) where he will discuss the company’s ongoing human clinical trials for XLRS and ACHM-B3.
  
  

• Alliance for Regenerative Medicine's 4^th Annual Cell & Gene Therapy Investor Day – New York, N.Y. (March 22)
  Sue Washer, President and CEO, will provide a company presentation on March 22nd at 4:05pm EDT. Ms. Washer will discuss key corporate milestones in addition to reviewing AGTC's clinical pipeline. To access a live webcast of this presentation, please visit http://arminvestorday.com/webcast/. A replay will be available at the same address shortly after the conference.

             
About AGTC

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.

AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis, X-linked retinitis pigmentosa, achromatopsia, wet age-related macular degeneration and blue cone monochromacy), non-ophthalmology programs in alpha-1 antitrypsin deficiency and adrenoleukodystrophy and early research studies in additional indications. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.

Forward Looking Statements

This release contains forward-looking statements that reflect AGTC's plans, estimates, assumptions and beliefs. These statements relate to a variety of matters, including but not limited to possible or assumed future results of operations, business strategies and operations, preclinical and clinical product development and regulatory progress, potential growth opportunities, potential market opportunities and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Actual results could differ materially from those discussed in the forward-looking statements, due to a number of important factors, which include, but are not limited to, the following: no gene therapy products have been approved in the United States and AGTC cannot predict when or if it will obtain regulatory approval to commercialize a product candidate; uncertainty regarding AGTC's ability to achieve the expected benefits from its collaborations with Biogen and others, including as a result of risks and uncertainties associated with drug development and commercialization; AGTC relies on third parties to conduct, supervise and monitor its clinical trials and to conduct certain aspects of its research, product manufacturing and protocol development; and increased regulatory scrutiny of gene therapy and genetic research could damage public perception of AGTC's product candidates or adversely affect AGTC's ability to conduct its business. Additional factors that could cause actual results to differ materially from those described in the forward-looking statements are set forth under the heading "Item 1A—Risk Factors" in AGTC's Annual Report on Form 10-K for the fiscal year ended June 30, 2015, as filed with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this release. Except as required by law, AGTC assumes no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

IR/PR CONTACTS:

David Carey (IR) or Danielle Lewis (PR)
Lazar Partners Ltd.
T: (212) 867-1768 or (212) 843-0211
[email protected] or [email protected]

CORPORATE CONTACTS:

Larry Bullock
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (386) 462-2204
[email protected]

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
[email protected]